Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services MALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of...Read more
SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000...Read more
The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of the Company's upcoming Co-Dx™ PCR platform and other Co-Dx IP SALT LAKE CITY, Sept. 16, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular...Read more
New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today highlighted newly published findings in Critical Care Explorations that define endotoxic septic...Read more
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. According to research, chromoanagenesis refers to a...Read more
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its...Read more
SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic...Read more
VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma"), the Company's wholly owned German subsidiary. Over the past several weeks, multiple proprietary film platforms were...Read more
PALO ALTO, Calif. / Sep 15, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans’ health care including the Centers for Medicare and...Read more
Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI (“MBody AI”) and Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger”). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI...Read more
1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward CHARLOTTE, N.C., Sept. 12, 2025 (GLOBE...Read more
SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of the primers sets used in its Co-Primers®-based PCR tests for the detection of chikungunya virus (or "CHIKV"), showing a high homology against over 1,200...Read more
CHICAGO / Sep 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image...Read more
Streamlined access to Guardant Shield ™ will help millions of people residing in senior living facilities to stay up to date on colorectal cancer screening LabFlorida/SunDX will provide patients in assisted and independent living communities, as well as residential care facilities across 20 states access to Shield LabFlorida exclusively distributing Shield in senior centers in Florida PALO ALTO, Calif. / Sep 11, 2025 / Business Wire...Read more
WILMINGTON, Mass. / Sep 11, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process...Read more
Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx Meningitis/Encephalitis (ME) Panel, sets standard with 16 targets for central nervous system infections and broadest coverage for fast and accurate diagnosis QIAstat-Dx panels offer unique advantages, including exclusive and medically valuable...Read more
Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio...Read more
RESEARCH TRIANGLE PARK, N.C. / Sep 10, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by...Read more
Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection Offered as a laboratory-developed test at $689 Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites MADISON, Wis. / Sep 10, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED)...Read more
HENDERSON, Nev., Sept. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the signing of a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") with Werfen's Immunoassay Technology Center, a worldwide leader in specialized diagnostics. Full terms of the agreement are confidential. Commenting on the...Read more
Real-world evidence demonstrates PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) CHICAGO / Sep 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the...Read more
bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO / Sep 09, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in which its flagship product,...Read more
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade dysplasia (LGD); current guidelines recommend prompt intervention for LGD to prevent disease progression FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company...Read more
LOS ANGELES, Sept. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer, and Mital Patel, Executive Vice President of Financial...Read more
Strategic partnership will expand Shield to PathGroup’s 15,000+ primary care and OBGYN physicians PathGroup’s extensive network of phlebotomists and Patient Service Centers enables easier access to Shield, the more pleasant and convenient way to screen for CRC PALO ALTO, Calif. / Sep 08, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with...Read more
BRANFORD, Conn. / Sep 08, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the launch of the V4 Sequencing Kit. The new kit is compatible with both the Platinum® and Platinum® Pro instruments. The V4 Sequencing Kit improves sequencing coverage with the addition of glycine (G)...Read more
WILMINGTON, Mass. / Sep 08, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, at 10:00 a.m. EDT; and Baird 2025 Global Healthcare Conference on Wednesday, September 10th, at 9:40 a.m. EDT. Management will present an overview of Charles...Read more
New study presented at HRX Live 2025 demonstrates continued advancement of company’s AI program HeartBeam's AI algorithm performed equally well on HeartBeam 3D ECG system and standard 12L ECGs in classifying atrial fibrillation, atrial flutter and sinus rhythm Deep learning algorithms to be used for future FDA submissions to enhance product offerings SANTA CLARA, Calif. / Sep 08, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT),...Read more
GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Total Revenues were RMB148.5 million (US$20.7 million) for the three months...Read more
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). One of the goals of this study was to determine whether patients...Read more
New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test service designed to help providers understand the patient's individual genetic response to select...Read more
Tempus’ generative AI-enabled clinical assistant is designed to support providers in unlocking new insights and efficiencies CHICAGO / Sep 04, 2025 / Business Wire / Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) today announced a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus’ generative-AI clinical co-pilot, within its electronic health...Read more
Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded clinical cohort derived from landmark ECLIPSE study PALO ALTO, Calif. / Sep 04, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the...Read more
DUBLIN / Sep 04, 2025 / Business Wire / ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON’s Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will...Read more
Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that...Read more
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO, Sept. 3, 2025 /CNW/ -- Illumina Inc. (NASDAQ: ILMN) today announced...Read more
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer MENLO PARK, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible...Read more
SANTA CLARA, Calif. / Sep 03, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP) 2025, taking place in Vienna, Austria, from September 6–10, 2025. Agilent will spotlight the European launch of its newly expanded Dako Omnis Family of instruments. The Dako Omnis family, including the Dako Omnis 110, 165, and 165 Duo models, is...Read more
Partnership aimed at improving cell separation and increasing cell viability WILMINGTON, Mass. / Sep 03, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Akadeum Life Sciences, a leader in advanced cell separation technologies, announced today the integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program. Charles River’s Cell Therapy Flex...Read more
SOUTH SAN FRANCISCO, Calif. / Sep 03, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025 at 9:40 am Eastern Time in New York City. The company will also host one-on-one meetings at the Morgan Stanley 23rd...Read more
U.S. patent protection covers computer-aided diagnosis (“CADx”) with breast CT Izotropic holds the exclusive rights to this patent and breast CT technology under global license agreement CADx upgrade to be integrated into IzoView Breast CT post-initial market launch, feature may be offered as an upgrade incentive to early adopters VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE)...Read more
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals,...Read more
BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9. To access...Read more
SOUTH SAN FRANCISCO, Calif. / Sep 02, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL). “With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel...Read more
SANTA CLARA, Calif. / Sep 02, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with...Read more
BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and is now authorized for marketing in the United Kingdom. This milestone...Read more
New customer launches representing 107,000 lives covered reinforce Dario's B2B2C momentum and recurring revenue growth Dario's multi-condition digital health solutions deliver real-time results for prediabetes, diabetes, and hypertension resulting in a 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user 80% of the new accounts signed in 2025 are for multi-condition...Read more
Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in pre-employment testing, according to the 2025 Quest Diagnostics Drug Testing Index™ from Quest Diagnostics (NYSE: DGX), a leading provider of...Read more
VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:XPHYF) (FSE:4XT) is pleased to announce the receipt of the Semaglutide active pharmaceutical ingredient (API), enabling the initiation of laboratory-scale formulation and testing of the Company's oral dissolvable film (ODF) delivery system. In collaboration with its qualified supply partners, BioNxt has secured...Read more
U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflow QIAstat-Dx Rise launch can process up to 160 samples per day, initial launch includes Respiratory Panel Plus and Respiratory Panel Mini and additional panels in development Expansion of QIAstat-Dx instrument portfolio in the U.S. builds on the availability of both system...Read more
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended June 30, 2025 (the "second quarter"). "We are focused on advancing our CID-103 program, a potentially...Read more
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and six months ended June 30, 2025. Financial and Operational Highlights Revenues were $4.7 million in the second quarter compared to $4.4 million in the same period the prior year, an increase of 6.2%. For the six months...Read more
SALT LAKE CITY, Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27th Annual Global Investment Conference on Friday, September 5, 2025 at 7:00 a.m. ET. Zhenya Lindgardt, President and CEO, will...Read more
Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28,...Read more
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic collaboration to accelerate the development of breakthrough life sciences companies. The collaboration will help the Flagship ecosystem of...Read more
Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas / Aug 28, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating whether a...Read more
Agilent delivers strong revenue growth, raises growth outlook Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core(1) basis compared with the third quarter of 2024. GAAP net income of $336 million; earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024. Non-GAAP(2) net income of $390 million; EPS...Read more
MILFORD, Mass., Aug. 26, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Thursday, September 4th, 2025, at 9:30 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website...Read more
Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state Quest will also manage Corewell Health's 21 hospital labs SOUTHFIELD, Mich. and GRAND RAPIDS, Mich. and SECAUCUS, N.J., Aug. 26, 2025 /PRNewswire/ -- Corewell Health and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, have signed a definitive agreement to enter into a joint...Read more
SAN DIEGO / Aug 26, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT) The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT) Links to the webcast will be available on the Dexcom Investor...Read more
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 26, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it intends to complete a small non-brokered private placement...Read more
SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy...Read more
AUSTIN, Texas / Aug 25, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of Signatera in lung cancer. An analysis of...Read more
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8th, 2025. Conference & Webcast Details Date: September 8, 2025 Time: 3:00 p.m. to 3:30 p.m. ET Presenter: Erik Holmlin, PhD, CEO of...Read more
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making thresholds for adjuvant radiation therapy and surveillance imaging FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...Read more
Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated CHICAGO / Aug 22, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to...Read more
AUSTIN, Texas / Aug 22, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and reinforcing its long-standing commitment to robust clinical evidence and scientific research. These publications span high-impact journals – such as Nature, Nature Medicine, the American Journal of...Read more
DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director. Mr. Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance across...Read more
Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader Profitability and Growth Objectives DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology...Read more
SANTA CLARA, Calif. / Aug 20, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo® (nivolumab) alone or Opdivo (nivolumab) in...Read more
VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce two key milestones in the expansion and protection of its proprietary drug delivery platform targeting neurological autoimmune disorders. The Company has formally initiated the prioritized examination...Read more
Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test GUILDFORD, SURREY / ACCESS Newswire / August 20, 2025 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has...Read more
SOUTH SAN FRANCISCO, Calif. / Aug 19, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy...Read more
SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government...Read more
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately. Nilesh brings over 25 years of leadership experience in the medical technology and life sciences industries, having held senior roles at Johnson & Johnson, GE Healthcare and most recently, West...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE